Tachyon Announces Presentation at the 2021 ESMO Annual Meeting

On September 17, 2021 Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and development biotechnology company, reported an abstract presentation of the Company’s lead product candidate, TACH101, at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) ("ESMO") Annual Meeting. ESMO (Free ESMO Whitepaper) is being held virtually from September 16-21, 2021 (Press release, Tachyon Therapeutics, SEP 17, 2021, View Source [SID1234587904]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Triple negative breast cancer represents nearly 20% of all breast cancers and is a highly aggressive subtype that continues to have poor prognosis due to lack of effective treatments," stated Frank Perabo, MD, PhD, CEO of Tachyon Therapeutics. "Large-scale genomic analysis projects show that KDM4 is amplified in about 25% of triple negative breast cancer cases, making KDM4 an attractive epigenetic target for this cancer type. We are anticipating to study TACH101 in the near future in clinical trials."

Highlights from the ESMO (Free ESMO Whitepaper) abstract are summarized below:

Abstract #210P

TACH101 was potent in killing a Triple Negative Breast Cancer (TNBC) cell line (MDA-MB-231) with an IC50 of 0.0035 µM.
TACH101 treatment of MDA-MB-231 TNBC cells caused cell-cycle arrest and induction of apoptosis with an EC50 of 0.132 µM.
In vivo, TACH101 inhibited tumor growth in the COH70 TNBC xenograft model with tumor growth inhibition > 85%.
Gene expression analysis of TACH101-treated tumors show that Protein Phosphatase 1 Regulatory subunit 10 (PPP1R10 or PNUTS), a key regulator of the retinoblastoma protein (Rb) and p53, was a direct target of KDM4 and was significant downregulated after 24 hours of treatment.
The poster presentation of Abstract #210P is available for viewing on the ESMO (Free ESMO Whitepaper) Annual Meeting website at View Source